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Radiation therapy (RT) is a curative treatment option for localized prostate cancer. Prostate irradiation
with focal dose escalation to the intraprostatic dominant nodule (IDN) is an emerging treatment
option that involves the prophylactic irradiation of the whole prostate while increasing RT doses to the
visible prostatic tumor. Because of the lack of large multicentre trials, a systematic review was per-
formed in an attempt to get an overview on the feasibility and efﬁcacy of focal dose escalation to the
IDN.
A bibliographic search for articles in English, which were listed in MEDLINE from 2000 to 2016 to
identify publications on RT with focal directed boost to the IDN, was performed. The review was
completed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses
guidelines.
Twenty-two articles describing 1,378 patients treated with RT using focal boost were identiﬁed and
fulﬁlled the selection criteria. Intensity-modulated radiation therapy (IMRT) was used in 720 patients
(52.3%), volumetric modulated arc therapy was used in 45 patients (3.3%), stereotactic body radiation
therapy (SBRT) in 113 patients (8.2%), and lowedose rate and highedose rate brachytherapy (BT) were
used in 305 patients (22.1%) and 195 patients (14.1%), respectively. Use of androgen deprivation therapy
varied substantially among series. Biochemical disease-free survival at 5 years was reported for a cohort
of 812 (58.9%) patients. The combined median biochemical disease-free survival for this group of patients
was 85% (range: 78.8e100%; 95% conﬁdence interval: 77.1e82.7%).
The average occurrence of grade III or worse gastrointestinal and genitourinary late toxicity was,
respectively, 2.5% and 3.1% for intensity-modulated RT boost, 10% and 6% for stereotactic body RT, 6% and
2% for lowedose rate BT, and 4% and 4.3% for highedose rate BT.
This review shows encouraging results for focal dose escalation to the IDN with acceptable short- to
medium-term side effects and biochemical disease control rates. However, owing to the heterogeneity of
patient population and the short follow-up, the results should be interpreted with caution. Considering
that the clinical endpoint in the studies was biochemical recurrence, the use and duration of androgen
deprivation therapy administration should be carefully considered before driving deﬁnitive conclusions.
Randomized trials with long-term follow-up are needed before this technique can be generally
recommended.
© 2018 Asian Paciﬁc Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is among the third most common malig-
nancy in Europe. An estimated 417,000 PCa cases were diagnosed in
Europe in 20121 and 1.4 million cases of PCa worldwide withausanne, Switzerland.
errera).
te Society, Published by Elsevier293,000 deaths in 20132. Traditionally, PCa patients have been
considered for active surveillance programs or radical whole-gland
therapies such as prostatectomy, external beam radiotherapy
(EBRT), or brachytherapy (BT)3. In the case of EBRT, the advent of
more sophisticated treatment plans yields better dose conformity
to the target, allowing for dose escalation and better biochemical
disease control, although not without toxicity because of the close
proximity of organs at risk (OARs), particularly bladder and
rectum4e10.Korea LLC. This is an open access article under the CC BY-NC-ND license (http://
Abbreviations
ADT Androgen deprivation therapy
ADC Apparent diffusion coefﬁcient
BED Biological equivalent dose
bDFS Biological disease-free survival
BT Brachytherapy
CTCAE Common Terminology Criteria for Adverse Events
CBCT Cone-beam Computed tomography
DWI Diffusion-weighted imaging
DCE Dynamics contrast enhancement
DSS Disease-speciﬁc survival
EBRT External beam radiotherapy
ERC Endorectal coil
GI Gastrointestinal
GU Genitourinary
Gy Gray
GTV Gross tumor volume
HDR Highedose rate brachytherapy
IMRT Intensity-modulated radiation therapy
IGRT Image-guided radiation therapy
IDN Intraprostatic dominant nodule
KVCT Kilovoltage Computed tomography
LDR Low dose rate
LC Local control
MRSI Magnetic resonance spectroscopy imaging
MVCT Megavoltage computed tomography
mpMRI Multiparametric Magnetic Resonance Imaging
NCCN National Comprehensive Cancer Network
OAR Organs at risk
OS Overall survival
PET CT Positron emission computed tomography
PCa Prostate cancer
PSA Prostatic Speciﬁc Antigen
PTV Planning Target Volume
PTVb PTV boost
PTVpr PTV prostate
SIB Simultaneous integrated boost
SPECT Single-Photon Emission Computed Tomography
SUV Standard Uptake Value
SBRT Stereotactic body radiation therapy
T2W T2-weighted sequence
US Ultrasound
VMAT Volumetric modulated arc therapy
Prostate International 6 (2018) 75e8776Randomized data comparing different methods of dose escala-
tion are sparse, with three randomized trials comparing EBRT plus
whole prostate BT boost with EBRT alone. These trials have
demonstrated improved biochemical disease-free survival (bDFS)
using distinct BT boost regimens, but only the Androgen Suppres-
sion Combined with Elective Nodal and Dose Escalated Radiation
Therapy (ASCENDE-RT) trial has shown signiﬁcantly greater uri-
nary side effects11e14.
Importantly, studies of patterns of failure after conventionally
fractionated EBRT show that the area responsible for local recur-
rence is the intraprostatic dominant nodule (IDN) in 90% of
cases15e18. The IDN is deﬁned as the largest nodule in a multifocal
disease which harbors in more than 80% of the cases the most
aggressive biological behavior and therefore dictates the overall
clinical prognosis of PCa19.
Retrospective studies compared the site of the primary tumor
on pre- and post-EBRT magnetic resonance images (MRIs), and by
using large block pathology sections of the salvage radical prosta-
tectomy specimen as the reference gold standard, they mapped the
position of the recurrent tumor within the prostate showing that
the pre-EBRT intraprostatic dominant nodule visible on the MRI
was responsible for the local recurrence and could be speciﬁcally
targeted to receive higher doses of radiation15e18.
Intraprostatic dose escalation requires advanced imaging capa-
bilities, which can detect intraprostatic tumor deposits with
acceptable sensibility and speciﬁcity. Nowadays, it is possible to
identify the IDNbyusingmultiparametricmagnetic resonance image
(mpMRI), which uses various T1 andT2 sequences, dynamic contrast
enhancement to assess perfusion, anddiffusion-weighted imaging to
calculate the different diffusion capability of PCa versus normal tis-
sue20. Other imagingmethods to detect the IDN such as 11C-choline-
positron emission computed tomography (PET/CT), 68Ga-prostate-
speciﬁc membrane antigen (PSMA) PET/CT, and newer generation
ultrasound equipment are also under evaluation21e24.
Furthermore, highly conformational EBRT techniques with
improvement in patient positioning during treatment, such as
image-guided radiation therapy (IGRT) and the use of ﬁducial
markers to track prostate movements during a radiotherapy ses-
sion, are needed for safe and effective treatment delivery25e27.Because of the lack of large multicentric trials, a systematic re-
view was performed in an attempt to get an overview on the
feasibility and efﬁcacy of focal dose escalation to the IDN, with
special attention to gastrointestinal (GI) and genitourinary (GU)
toxicity as well as clinical efﬁcacy.
2. Materials and methods
2.1. Literature search strategy
The literature review included a search in MEDLINE from 2000
to 2016, using the terms “intraprostatic” OR “intra-prostatic” OR
“dominant intraprostatic lesion” OR “intraprostatic lesion” OR
“gross tumor volume (GTV)” OR “simultaneous integrated boost”
AND “radiation” OR “radiation therapy” OR “brachytherapy” OR
“stereotactic body radiation therapy (SBRT)” OR “intensity modu-
lated radiation therapy (IMRT)” OR “volumetric arc therapy
(VMAT)” AND “prostate cancer”.
2.2. Assessment of study quality and inclusion criteria
The search results were assessed on content before inclusion
into the review. The selection criteria for inclusion in the systematic
review were accessible fully published articles in English, which
reported the treatment outcome of PCa patients who received a
boost to the IDN either by BT or EBRT. The primary endpoint was
treatment-related side effects and efﬁcacy outcome.
Articles dealing with case reports, recurrent disease, or planning
studies were not included. Reports from conference proceedings
were excluded. All authors participated in the design of the search
strategy and inclusion criteria.
The following data were extracted from each study: pre-
deﬁned eligibility criteria, year of report, sample size, type of
treatment, histology Gleason score, TNM stage, National
Comprehensive Cancer Network cancer risk classiﬁcation, median
prostate-speciﬁc antigen, median time of follow-up, pretreat-
ment diagnostic tools, such as imaging techniques used to
localize the disease, radiotherapy technique and dose, use of
androgen deprivation therapy (ADT), follow-up duration, acute
T. Feutren and F.G. Herrera / Prostate irradiation with focal IDN boost: systematic review 77and late side effects, quality of life assessment, biochemical
control, and when available disease-speciﬁc survival (DSS),
overall survival (OS), and local control rate. The side effects were
translated into the current classiﬁcation of adverse events Com-
mon Terminology Criteria of Adverse Events version 4. Acute
radiation effects are seen from day 1 through day 90, whereas
late radiation effects are all adverse effects seen after 90 days
from the beginning of RT.2.3. Statistical considerations
The outcomewas analyzed in terms of local control, DSS, and OS
rates at 5 years. If available, estimates and 95% conﬁdence intervals
(CI), as reported in the articles, were used. To perform meta-
analysis of median survival, we pooled the estimates as median
survival and standard error. Ninety-ﬁve CIs were extrapolated and
reported on variation, number of events, and/or median follow-up
times using RStudio software, version 1.0.153.
Given the heterogeneous nature of the patient series reported,
no formal attempt at a quantitation of bias or analysis of pooled
results was attempted; however, qualitative appraisal of the rela-
tive strengths and weaknesses of the individual series was made,Fig. 1. Diagram showing the results from the literature search using PubMed and from the
treatment using focal dose irradiation to the intraprostatic dominant nodule.and qualitative statements are included in the results and discus-
sion of the articles.
3. Results
In total, twenty-two articles describing 1,378 patients were
identiﬁed for data extraction. A Preferred Reporting Items for Sys-
tematic Reviews and Meta-analyses ﬂow diagram of the search
results is available in Fig. 1. Table 1 summarizes a patient's char-
acteristics, type of radiotherapy delivery, and outcome.
The level of the evidence is low to medium, with no study
yielding a level of evidence >2b. This suggests that the results of
this review should be interpreted with caution. Of particular
importance is the fact that we were unable to retrieve the exact
deﬁnition of IDN used in each study.
The median follow-up for the 1,378 patients was 36 months
(range 3e86 months).
3.1. Patient's characteristics
The analyzed literature28e49 included 323 (23%) patients with
National Comprehensive Cancer Network low-risk disease, 509
(37%) patients with intermediate-risk disease, and 517 (38%)selection of articles, resulting in the withholding of 22 articles reporting on results of
Table 1
Literature summary of prostate irradiation with intraprostatic directed boost
Author N IDN identiﬁcation modality Treatment technique NCCN Median PSA
(mg/L)
Median
follow-up
time
Volume delineation
and margins
Boost
technique
Dose (Gy/fr) ADT 5-year
bDFS
(phoenix)
Survival
(DSS, OS)
Zelefsky et al28 4 1,5T ERC MRSI (elevated
choline þ elevated
creatine-to-citrate ratio)
LDR B
(I125)
LR (2)
IR (2)
HR (0)
4.5 NR PTVb ¼ GTV
PTVpr ¼
prostate
LDR B
(I125)
PTVb ¼ 150%
of PTVpr
PTVpr ¼ 100e145
Gy
No NR NR
DiBiase et al29 15 1,5T ERC MRSI (elevated
choline þ elevated
creatine-to-citrate ratio)
LDR B
(I125)
LR (15)
IR (0)
HR (0)
7.1 NR PTVb ¼ GTV
PTVpr ¼
prostate þ
2 mm
LDR B
(I125)
PTVb ¼ 188 Gy
PTVpr ¼ 145 Gy
No NR NR
De Meerleer
et al30
15 1,5T ERC MRI
(T2W) þ biopsy
IMRT
(3 ﬁeld, Step
and Shoot)
LR (2)
IR (8)
HR (5)
10.2 NR PTVb ¼ GTV
PTVpr¼
(prostate þ SV)þ
7e10 mm
IMRT PTVb ¼
80 Gy/37
PTVpr ¼ 74
Gy/37
Yes
(73%)
neoadj þ adj
(6e36 mo)
NR NR
Singh et al31 3 3T ERC MRI
(T2W þ DCE
þ DWI) þ biopsy
IMRT NR NR 3e18 PTVb ¼ GTV þ 3 mm
PTVpr ¼ prostate þ 7
mm
PTVb ¼ 94,5 Gy/42
PTVpr ¼ 75,6 Gy/
42
No NR NR
Fonteyne
et al32
230 1,5T ERC MRI
(T2W þ T1W)
or MRSI
IMRT
(3 ﬁeld,
Step and Shoot)
LR (17)
IR (97)
HR (116)
11.2 NR PTVb ¼ GTV þ 4 mm
PTVpr¼ (prostate ± SV)
þ 4 mm
IMRT PTVb ¼ 80 Gy/39
PTVpr ¼ 78 Gy/39
No NR NR
Ares et al33 77 ERC MRI (T2W þ DCE)
þbiopsy
3DCRT þ HDR
B (Ir192)
LR (6)
IR (25)
HR (46)
NR 41.2 PTVb ¼ boost prostate
volume
PTVpr ¼ prostate þ VS
PLN
HDR B (Ir192) PTVb ¼ 85.6-99.2
Gy
PTVpr ¼ 64 Gy/32
Yes (>80%)
neoadj/adj
(18e24 mo)
78.8% 90% 5-year DSS
Miralbell
et al34
50 ERC MRI (T2W þ DCE)
þbiopsy
3DCRT/IMRT (Step
and shoot, sliding
window and
VMAT)
LR (5)
IR (12)
HR (33)
NR NR PTVb ¼ GTV þ 3 mm
PTVpr ¼ prostate þ SV
PLN
SBRT PTVb ¼ 80-99 Gy
PTVpr ¼ 64 Gy/32
Yes
(66%)
neoadj þ adj
(6-30 mo)
98% 100% 5-year DSS
Schick et al35 77 ERC MRI (T2W þ DCE)
þbiopsy
3DCRT þ HDR
B (Ir192)
LR (7)
IR (9)
HR (61)
NR 62e67 PTVb ¼ hemi prostate
PTVpr ¼ prostate þ vs
PLN
HDR B (Ir192) PTVb ¼ 88-104 Gy
PTVpr ¼ 64.4 Gy/
32
Yes
(81%)
neoadj þ adj
(18e24 mo)
70.5e79.7% NR
Ellis et al36,37 239 111In-Capromab SPECT
Imaging
LDR prostate þ
3DCRT in 37%
LR (116)
IR (94)
HR (29)
7.6 84 PTVb ¼ GTV þ 5 mm
PTVpr ¼ prostate þ 2
e5 mm
±PLN
LDR prostate
(Pd103 or I125)
PTVb ¼ 150% of
PTVpr
PTVpr ¼ 108e144
Gy (I125)
PTVpr ¼ 100e125
Gy (Pd103)
Yes
(21%)
neoadj
84.6% 97.7% 10-year DSS
84.8% 10-year OS
Wong et al38 71 111In-Capromab SPECT
Imaging
IMRT LR (31)
IR (30)
HR (10)
6.1 66 PTVb ¼ GTV
PTVpr ¼ prostate þ SV
(when involved) þ 6
mm
IMRT PTVb ¼ 82 Gy (SIB)
PTVpr ¼ 75.6 Gy/
42
Yes
(24%)
adj
(6e12 mo)
94% 93% 5-year OS
Pinkawa
et al39
66 18F-Fluorocholine PET CT IMRT LR (23)
IR (21)
HR (22)
14 19 PTVb ¼ GTV þ 3-4 mm
PTVpr ¼ prostate þ SV
þ 4e8 mm
IMRT PTVb ¼
80 Gy (SIB)
PTVpr ¼ 76 Gy/38
Yes
(16%)
(NR)
NR NR
Ippolito
et al40
40 1,5T ERC MRI þ biopsy IMRT LR (4)
IR (17)
HR (19)
7 19 PTVb¼ (GTV þ 5 mm)þ
1 cm
PTVpr ¼ prostate þ SV
þ 1 cm
IMRT PTVb ¼ 80 Gy (SIB)
PTVpr ¼ 72 Gy/40
Yes
(100%)
neoadj þ adj(24 mo)
100% NR
Myers et al41 26 TRUS IMRTþ
HDR B (Ir192)
LR (7)
IR(19)
HR (0)
6.1 53 PTVb¼ peripheral zone
PTVpr ¼ (prostateþ1.5
cm þ VS þ 5 mm) þ
5 mm
PLN
HDR B (Ir192) PTVb ¼ 9 Gy þ 63
Gy/28
PTVpr ¼ 6Gy þ 63
Gy/28
Yes
(73%)
neoadj þ adj(4 mo)
100% NR
Aluwini
et al42
50 1.5 T MRI (T1W þ T2W) SBRT (Cyberknife) LR (30)
IR (20)
HR (0)
8.2 23 PTVb ¼ GTV
PTVpr ¼ prostate þ 3
mm
SBRT
(Cyberknife)
PTVb ¼
44 Gy (SIB)
PTVpr ¼
38 Gy/4, daily
No 100% 2-year bDFS NR
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Schild et al43 78 1.5 T MRI (T2W þ DCE þ
DWI)
IMRT (sliding
window and
VMAT)
LR (18)
IR (43)
HR (17)
6.7 36 PTVb ¼ GTV
PTVpr ¼ prostate þ 3
mm
IMRT (sliding
window
and VMAT)
PTVb ¼
81-83 Gy (SIB)
PTVpr ¼ 77,4 Gy/
43
Yes
(41%)
adj(6e30 mo)
92% 3-year bDFS 95% 3-year OS
Gomez-
Iturriaga
et al44
15 1.5 T MRI (T2W þ DCE þ
DWI)
IMRT þ HDR
B (Ir192)
LR (0)
IR and HR: not
speciﬁed
9 18 PTVb ¼ GTV
PTVpr ¼ prostate
HDR B (Ir192) PTVb¼ 18.75 Gyþ
37.5 Gy/15
PTVpr ¼ 15 Gy þ
37.5 Gy/15
No NR NR
King et al45 47 MRSI (elevated choline þ
elevated creatine-to-
citrate ratio)
LDR (I125or
Pd103) þ IMRT PLN
for 1 patient
LR (35)
IR (12)
HR (0)
5.1 86.4 PTVb ¼ GTV
PTVpr ¼ prostate
PLN
LDR
(I125 or Pd103)
PTVb ¼
150% of PTVpr
PTVpr ¼ 144 Gy
(I125) or 140 Gy
(Pd103)
Yes
(17%)
neoadj
98% 10-year bDFS 84% 10-year OS
Sundahl et al46 225 1,5T ERC MRI or 3T MRI
(T1W þ T2W)
IMRT LR (5)
IR (97)
HR (123)
NR 72 PTVb ¼ GTV
PTVpr ¼ prostate ± SV
þ 7 mm
IMRT PTV1¼ 82 Gy (SIB)
PTV2 ¼ 78 Gy/38
No 84% 6-year bDFS NR
Kotecha et al47 24 MRI (no speciﬁcation) SBRT (Cyberknife) LR (0)
IR (11)
HR (13)
NR 25 PTVb ¼ GTV
PTVpr ¼ prostate þ
SVþ3 mm(0 mm
posteriorly)
SBRT (Cyberknife) PTVb¼ 50 Gy (SIB)
PTVpr ¼ 36.25 Gy/
5
Yes
(67%)
Adj(4e30 mo)
95.8% 2-year bDFS NR
Uzan et al 48 11 MRI (T2W þ DCE þ DWI) þ
biopsy
IMRT (VMAT) NR 15.9 36 PTVb ¼ GTV þ 5 mm
PTVpr 1 ¼ prostate þ
SV þ 9 mm
PTVpr 2 ¼ prostate and
base of SV þ 5 mm
IMRT (VMAT) PTVb ¼
85e105 Gy (SIB)
PTVpr1 ¼ 64 Gy/
37
PTVpr2 ¼ 74 Gy/
37
Yes
(100%)
neoadj þ adj
(6e36 mo)
NR NR
Garibaldi
et al49
15 1.5 ERC MRI (T2W þ DWI þ
DCE)
IMRT (VMAT) LR (0)
IR (14)
HR (1)
6.5 16 PTVb ¼ GTV þ
6 mm
PTVpr 1 ¼ prostate þ 7
mm (5 mm
posteriorly)
PTVpr 2 ¼ SV þ 5e7
mm
IMRT (VMAT) PTVb ¼ 83.2 Gy
(SIB)
PTVpr1 ¼ 75.2 Gy/
32
PTVpr2 ¼ 67.2 Gy/
32
Yes
(80%)
neoadj þ adj
(6e24 mo)
100% NR
3DCRT, 3-D conformational radiation therapy; ADT, androgen deprivation therapy; Adj, adjuvant ADT; bDFS, biochemical disease-free survival; CTCAE v2, Common Terminology Criteria of Adverse Events version 2, CTCAE v4,
Common Terminology Criteria of Adverse Events version 4; DCE, dynamic contrast enhancement; DSS, disease-speciﬁc survival; EORTC, European Organization for Research and Treatment for Cancer; DWI, diffusion-weighted
imaging; EPIC, Expanded Prostate Cancer Index Composite questionnaire; ERC, endorectal coil; Fr, fraction; GI, gastrointestinal; GTV, Gross tumor volume (¼dominant intraprostatic lesion); GU, genitourinary; Gy, gray; HDR,
highedose rate brachytherapy; HR, high risk; IDN, intraprostatic dominant nodule; IMRT, intensity-modulated radiation therapy; IR, intermediate risk; LDR B, lowedose rate brachytherapy; LR, low risk; MRI, magnetic
resonance imaging; mpMRI, multiparametric MRI [T2 weighed þ dynamic contrast enhancement (DCE) þ diffusion-weighted imaging (DWI)]; MRSI, magnetic resonance spectroscopic imaging; NCCN, National Comprehensive
Cancer Network; Neoadj, neoadjuvant ADT; NR, not reported; OS, overall survival; PET CT, positron emission tomographyecomputed tomography; PLN, pelvic lymph nodes irradiation; PLND, pelvic lymph nodes dissection; PSA,
prostate-speciﬁc antigen; PTV, planning target volume; PTVb, boost; PTVpr, whole prostate; SBRT, stereotactic body radiation therapy; SPECT, single-photon emission computed tomography; SV, seminal vesicles; TRUS,
transrectal ultrasound; VMAT, volumetric modulated arc therapy.
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Prostate International 6 (2018) 75e8780patients with high-risk disease. Three studies did not specify the
risk group (29 patients, 2.1%).
3.2. Disease localization
The spatial location of the tumor within the prostate is essential
for dose escalation of radiotherapy treatment. There is no accepted
standard for disease localization for the purpose of delivering boost
therapy.
In 976 patients (70.8%; n ¼ 17 studies), an MRI was used to
identify the IDN. From those series, ﬁve (488 patients, 35.4%) used
magnetic resonance spectroscopy imaging (Choline/creatine-to-
citrate ratios >1.4e2) to deﬁne the tumor28,29,32,33,45, three series
(116 patients, 8.4%) used 3T MRI, and nine series (438 patients,
31.7%) used mpMRI (with sequences T2W þ dynamic contrast
enhancement þ diffusion-weighted imaging)31,33e35,43,44,46,49,48, of
which two studies used open MRI33,35.
Six hundred ninety-eight patients (71.5%) (n¼ 15 studies) of 976
underwent 1.5 T magnetic resonance imaging with an endorectal
coil to identify the IDN. Two series (162 patients, 16.6%) used MRI
without an endorectal coil42,46.
One study with 66 patients (4.8%) used 18-Fluorocholine PET/CT
imaging39 [withagross tumorvolume (GTV)¼ standarduptakevalue
(SUV) > 2  background]. Three studies (310 patients, 22.5%) used
111In-Capromab single-photon emission computed tomography36e38
(with a GTV ¼ SUV 3 muscle SUV) for tumor localization.
Only one study (26 patients, 1.9%) used transrectal ultrasound
(TRUS) to identify the tumor during the HDR BT treatment41. In 476
patients (49.9%) treated with BT, the procedure was delivered un-
der US (n ¼ 7 studies, 3 studies with transrectal and 4 studies with
transabdominal US).
The mean percentage of IDN identiﬁed and irradiated was 80.4%
(range 28e100%).
3.3. Radiotherapy planning
MRIs, PET CT, or single-photon emission computed tomography
images used to identify the IDN were transferred to the radio-
therapy planning computed tomography images through auto-
matic rigid image registration (1079 patients, 78.3%, n ¼ 16
studies)31e35,38e40,42e49 or manual transfer (269 patients, 19.5%,
n¼ 4 studies)29,30,36,37. The visible tumor was considered as GTV by
all the studies. Most series deﬁned the planning target volume
(PTV) as the GTV with an extension of 3- to 4-mm margins,
excluding OARs. None of the studies used a margin for clinical
target volume around the GTV, and thus, the boost PTV comprised
the tumor with a margin of 1e3 mm. The prostate PTV deﬁnition
varied among series. It most commonly included
prostate þ seminal vesicles when they were involved and an
isotropic extension of 3e7 mm.
Deformable registration was used in only one study (4 patients,
0.3%)28. Fiducial markers were used for tracking intrafraction and
interfraction tumor movement in ﬁve studies (168 patients,
12.2%)31,41e43,48.
In the case of BT, only one study (26 patients, 1.9%)41 used TRUS
to deﬁne the IDN.
3.4. Protection of healthy tissue
OARs contouring guidelines varied among studies, and most of
the studies considered rectum, bladder, and bowel as critical organs
to be preserved from high doses of radiation. Efforts to spare the
urethra were made in 14 studies (830 patients, 60.2%)
A total of 127 patients (9.2%) in two studies were treated with a
rectal balloon to reduce internal organ immobilization33,34.3.5. Radiotherapy delivery
A total of 878 patients (63.7%) were treatedwith EBRTwith focal
boost using
1. IMRT (720 patients, 52.3%, n ¼ 8 studies)
2. VMAT (34 patients, 2.5%, n ¼ 3 studies)
3. SBRT (124 patients, 8.9%, n ¼ 3 studies). Fig. 2
A total of 500 patients (36.3%) were treated with BT with focal
boost using
4. Lowedose rate brachytherapy (LDR BT) (305 patients, 22.1%,
n ¼ 4 studies)
5. HDR BT (195 patients, 14.1%, n ¼ 4 studies).3.6. External beam radiation therapy setup monitoring
Online corrections through IGRT to minimize patients' setup
uncertainty were used at different frequencies in 941 patients
(68.2%; n ¼ 15 studies). Fifteen patients of 941 (1.5%) were moni-
tored with daily megavoltage computed tomography (n ¼ 1 study),
236 patients (25%) were monitored with daily cone-beam CT
(n ¼ 2), 152 patients (16.1%) were monitored with kilovoltage
computed tomography (n ¼ 3), 18 patients (1.9%) with daily portal
images (n ¼ 1), and 50 patients (5.3%) with daily monitoring of
infrared skin-reﬂecting markers.
Fiducial markers were used for tracking intrafraction and
interfraction tumor movement in ﬁve studies (168 patients,
12.2%)31,41e43,48.3.7. Target doses and organs at risk dose constraints
For the purpose of this review, all doses were converted to EQD2
(equivalent dose in 2-Gy fractions) with a/b ¼ 1.5 Gy for pros-
tate50,51 and a/b ¼ 3 Gy for OARs.
Most of the studies using EBRT prescribed the radiation dose to
isocenter to cover homogeneously 98e100% of the prostate PTV.
For IMRT series, the mean doses delivered to the PTV boost (PTVb)
were 89 Gy (range 80e130 Gy), and the mean dose to the prostate
PTV was 74.7 Gy (range 67.9e82.7 Gy). The average differential
dose [PTVbePTV prostate (PTVpr)] was 14.8 Gy (range
3.2e29.9 Gy).
For the VMAT series, the mean dose to the PTVb and PTVpr were
104 Gy (range 92.2e130 Gy) and 78 Gy (range 74e82,7 Gy),
respectively. The average differential dose was 26 Gy (range
17e35 Gy).
For the SBRT series, the PTVb and PTVpr mean doses were
136.4 Gy (range 89.7e164.3 Gy) and 91.4 Gy (range 64e119.4 Gy),
respectively. The average differential dose was 45 Gy (range
25.7e73.5 Gy). The most common EBRT rectal dose constraint was
V70 < 15e30% with rectal Dmax of 76e80 Gy. Bladder dose
constraint was V70 < 15e30% and Dmax of 80 Gy. The urethra
Dmax was 74e113 Gy when it was possible to spare, depending
on the modality used.
For the BT series, I125 or Pd103 LDR was most commonly used
with a mean PTVb and PTVpr dose of 177.5 Gy (range 150e217 Gy)
and 123 Gy (range 100e145 Gy), respectively. The average differ-
ential dose was 61.8 Gy (range 43e72 Gy). The urethra Dmax was
<85e150%of the PTVbdose and rectalDmaxwas<120%of thePTVb.
For HDR BT the mean dose for PTVb and PTVpr were 106.3 Gy
(range 89.7e151.3 Gy) and 80.5 Gy (range 64e113.6 Gy). The
average differential dose was 31.7 Gy (range 25.7e43.4 Gy).
Fig. 2. Stereotactic body radiation therapy plan using Cyberknife. The patient is treated in the context of the HYPORT phase I/II trial (NCT02254746) that the authors of this review
perform at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. The tumor is located in the right posterior prostate lobule. Fiducial markers are placed in the
prostate for robotic-assisted tracking purposes. A rectal balloon spares the rectum from high doses of radiation. The prostate is treated with 36.25 Gy in ﬁve fractions of 7.25 Gy with
a boost of 50 Gy to the intraprostatic dominant nodule. Red lines represent prescription isodose (80%).
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lymph node irradiation with a total dose of 50.4 Gy in 28
fractions33e35,41,45.
3.8. Androgen deprivation therapy
ADT varied among series.
A total of 384 patients (27.8%) in 15 studies were treated with
ADT30,33e41,43,45,47e49,52. Three hundred twenty-three patients of
384 (84%) in 12 studies were treated with adjuvant ADT. Neo-
adjuvant ADT was used in 300 patients (78%; n ¼ 10 studies)
Usually, EBRT started 1e3 months after the ﬁrst day of hormonal
blockage. The ADT lasted 6 months for intermediate-risk patients
and 2e3 years for high-risk patients.
3.9. Disease outcome
The median follow-up for the 1,378 patients was 36 months
(range 3e86 months).
bDFS at 5 years was reported for a cohort of 812 (58.9%) patients
in eight studies33e35,37,38,41,45,46. The median bDFS for these series
was 85% (range 78.8e100%; 95% CI: 77.1e82.7%). Fig. 3.
Other survival outcomes included 5- to 10-year OS which was
reported for 357 patients (25.9%) and had a median of 85% (range
from 84% to 93%). DSS was also studied for 366 patients (26.5%)
with a median of 97.7% at 5 years (range 90e100%).
3.10. Side effects
According to the RT technique, the median grade 3 or more
acute and late GI toxicity were 5% and 2.5% for IMRT boost,
respectively; 2% and 10% for SBRT, respectively; 0% and 6% (range
1e11%) for LDR BT, respectively; and 0% and 4% for HDR BT,
respectively.
Grade 3 or more acute and late GU toxicity were 4.4% (range
1e7%) and 3.1% (range 2e5%) for IMRT boost, respectively; 6%
(range 4e8%) and 6% for SBRT, respectively; 0% and 2% for LDR BT,
respectively; and 2.8% and 4.7% for HDR BT, respectively. Fig. 4.Grade 4 late GI toxicities was reported in four studies with a
median of 2% (range 1e4%). One study reported a 1% GU late grade 4
toxicity35e37. In these reports, three patients had rectovesical
ﬁstulae, and one had hematuria. The studies reporting late grade 4
toxicity used the following technology: IMRT (n ¼ 1 study), LDR BT
(n ¼ 2 studies), and HDR BT (n ¼ 1 study).
The acute and late grade 1e2 GI toxicity were 20.1% (range
6.6e45%) and 6.2% (range 0e21%) for IMRT boost, respectively; 6.7%
(range 0e12%) and 7% (range 3e10%) for SBRT, respectively; 21.3%
(range 0e60%) and 11.5% (range 2e21%) for LDR BT, respectively;
and 6.6% (range 2.6e13.4%) and 6.14% (range 0e11.5%) for HDR BT,
respectively.
The mean acute and late grade 1e2 GU toxicity were 39.2%
(range 13.3e66%) and 18.8% (range 5e39%) for IMRT boost,
respectively; 33% (range 15e46%) and 10% (range 8e12%) for SBRT,
respectively; 28.5% (range 4e53%) and 13% for LDR BT, respectively;
and 9.6% (range 3e20%) and 8.35% (range 6.7e11.5%) for HDR BT,
respectively Supplementary Fig. 5.4. Discussion
Multiple studies have conﬁrmed the importance of delivering
sufﬁciently high doses of radiotherapy to the prostate to cure pa-
tients4. First-class radiation technology and appropriate imaging
technology are absolute prerequisites to safely deliver higher focal
doses to prostate tumor/s.
In our review of the literature, we were able to identify 1,378
patients treated with whole prostate irradiation and dose escala-
tion to the IDN.
We showed that the adoption of new technologies is strongly
associated with an increase in the radiation doses delivered to the
IDN. The average differential doses between the prostate and the
boost increased with more complex technologies. Patients treated
with IMRT had modest differential doses between PTVpr and
PTVb of only 14.8 Gy compared with 25 and 45 Gy for those pa-
tients treated with VMAT and SBRT, respectively.
This systematic review highlights that when dose escalation
to the dominant nodule is delivered either with IMRT, VMAT,
Fig. 3. Forest plots presenting the 5-year biochemical disease-free survival with their calculated 95% conﬁdence interval from the included articles where this could be retrieved.
Prostate International 6 (2018) 75e8782SBRT, or BT, the functional and disease control outcomes are
encouraging. We showed that at a short-to-medium follow-up
time, the grade 3 or more GU and GI late toxicity were in the
order of 3% to 11%. We recognize that these rates may underes-
timate the true toxicity rates that may develop with longer
follow-up. Nevertheless, Fig. 4 and Supplementary Fig. 5 illus-
trate that the toxicities for the different modalities compare
favorably with those observed with other radiation modalities
depicted in Supplementary Table 2.
This is in striking contrast to studies of whole prostate dose
escalation using SBRT delivered in ﬁve fractions of 45, 47.5, and
50 Gy which showed 10.6% late grade 3 or more GI toxicity at the
highest dose level. In that study, late grade 3 or more rectal toxicity
was strongly correlated with the volume of rectal wall receiving
50 Gy > 3 cm3 (P < 0.0001) and treatment of >35% circumference of
rectal wall to 39 Gy (P ¼ 0.003)53. This highlights the need for
limiting the dose escalation to a deﬁned area of the prostate while
newmethods are needed for minimizing rectal toxicity. The use of a
rectal spacer has been proven in randomized trials to be an effective
method to reduce GI side effects and maintain the patient's quality
of life54. These methods should be implemented in future trials of
prostate dose escalation.
It is important to note that in our review, the series with the
highest boost differentials included 66 patients with reported late
grade 3 or greater toxicities that ranged from 0% to 10% including
one patient with ﬁstula formation34e37. This series used large (hemi
prostate or bilateral prostate GTV) volumes with relatively high
boost doses. More importantly, these series did not make any
attempt to protect the rectum with the use of a rectal spacer or
balloons to separate, as much as possible, the rectum from high
radiation doses.The side effects reported in our systemic review are not neces-
sarily different compared with other forms of PCa treatment.
Table 1, Fig. 3, Supplementary Table 2.
In general, GU toxicity has always remained a challenge for new
radiation technology. For instance, patients treated with IMRT or
3DCRT in the Radiation Therapy Oncology Group protocol14 had
40% incidence of GU grade 3 late toxicity. Ma et al55 recently pub-
lished a prospective study where 1,198 patients with different
urological complications were admitted in an emergency service.
Seventy-seven percentage of the admissions were elective and 23%
were emergency. Thirty-three patients of 1,198 had grade 3 or more
complications related to previous exposure to radiotherapy, rep-
resenting the 1.4% and 7.2% of the elective and emergency admis-
sions, respectively. From these 33 patients, 15 patients had PCa, and
four of them were initially treated with radical prostatectomy fol-
lowed by EBRT. The main mode of RT was EBRT (delivered in a
median of 34.5 fractions of 2 Gy, median dose 70 Gy). Importantly,
the median time from EBRT treatment to admission was 4 years
(range 1e9 years). This study highlights that although radiotherapy
complications represented a small proportion of the emergency
admissions, the gravity of the side effects trigger a surgical inter-
vention or invasive management many years after the primary
treatment. In linewith this observation, in the phase III randomized
ASCENDE-RT trial, the 5-year cumulative incidence of grade 3 or
more GU events was 18.4% for LDR-BT versus 5.2% for standard
78 Gy IMRT (P< 0.001). Along the same lines, the 5-year cumulative
incidence of grade 3 GI events was 8.1% for LDR-BT versus 3.2% for
standard EBRT (P ¼ 0.124).14 Protocols using protons or SBRT have
demonstrated very low incidence of severe side effects although
these comparisons of technology need to be corroborated in a
head-to-head clinical trial.
Fig. 4. Forest plots presenting the grade 3 or more: acute gastrointestinal (A), acute genitourinary toxicity (B), late gastrointestinal (C), and late genitourinary toxicity (D) with their
calculated 95% conﬁdence interval from the included articles where this could be retrieved.
IMRT, intensity-modulated radiation therapy; SBRT, stereotactic body radiation therapy; LDR, lowedose rate brachytherapy; HDR, highedose rate brachytherapy.
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at greater risk of toxicity after radiotherapy; therefore, large ran-
domized trials with long-term follow-up are required to see if new
radiotherapy treatments help all patients with PCa.
Our systematic review demonstrates that biochemical control
is achieved in 80e100% of cases when using directed dose esca-
lation to the IDN. The summary outcomes presented in Table 1
and Fig. 3 compared well with the historical EBRT trials and
other radiation series that used different modalities and have
mature follow-up. Supplementary Table 2. However, despite
these encouraging results and because of the variability of pa-
tient selection, use of ADT, and length of follow-up, it is difﬁcult
to preclude deﬁnitive statements regarding efﬁcacy of the boost
techniques.
King et al56 demonstrated the favorable therapeutic ratio ob-
tained in a consortium of patients from phase 2 whole prostate
SBRT trials who were treated between 2003 and 2011 at eightinstitutions. Five-year bDFSwas achieved in 95, 84, and 81% of low-,
intermediate-, and high-risk patients, respectively. The use of ADT
and SBRT dose did not signiﬁcantly affect bDFS even after strati-
fying by risk group. In a recent randomized trial that included 218
intermediate- to high-risk patients and that compared EBRT þ BT
boost (35.75 Gy in 13 fractions followed by a HDR-BT boost of
2  8.5 Gy in 24 h) versus EBRT (55 Gy in 20 fractions), there was a
signiﬁcant improvement in bDFS for EBRT þ HDR-BT, with a me-
dian time to relapse of 116 months compared with 74 months for
EBRT alone. The 5-, 7-, and 10-year bDFS estimates were 75%, 66%,
and 46% for EBRT þ HDR-BT boost compared with 61%, 48%, and
39% for EBRT alone (log rank P ¼ 0.04), with no signiﬁcant differ-
ence in side effects. In univariate and multivariate analysis, treat-
ment arm and risk category were signiﬁcant covariates for risk of
biochemical relapse as was the use of ADT13.
Although our systematic review exhaustively investigated
different aspects of patient selection, treatment delivery, and
Prostate International 6 (2018) 75e8784outcome, there were areas that could not be evaluated and there-
fore constitute the limitations of this study. Nevertheless, it is
pertinent to discuss these limitations and controversies in an
attempt to improve future trial designs. Owing to the heterogeneity
of patient selection, we were unable to determine the disease
outcome by risk category. The EBRT series reportedwere comprised
of primarily intermediate- to high-risk patients; the BT series
included a higher proportion of low-risk patients. It should be thus
highlighted that according to the natural history of PCa, dose
escalation RT should be delivered to patients who are likely to
beneﬁt from active treatment, whereas men with clinically insig-
niﬁcant disease should be monitored carefully by active
surveillance.
Speciﬁcally, the patients targeted with whole-gland dose irra-
diation and focal boost should be those with multifocal disease but
a clinically signiﬁcant nodule localized in one area of the prostate.
This dominant nodule has been reported to be responsible for local
recurrences and drives the natural history of the disease15e18,57,58.
In our systematic review, most of the studies used pretreatment
MRI as criteria to deﬁne the IDN. Although one investigator41 in our
review used TRUS, this method has been reported to be inaccurate
for localizing disease,59 and less information is available on PET/CT
imaging22. In general, it is accepted that imaging in the form of a
high-quality mpMRI reported by expert radiologists may have the
performance required to localize signiﬁcant areas of PCa. Evidence
is building to show that an area deemed negative on mpMRI stands
a 95% probability of having no clinically signiﬁcant disease as
deﬁned by the presence of any Gleason pattern 4 and/or a lesion
volume of 0.5 ml60,61. Nevertheless, the diagnostic accuracy of
mpMRI to detect IDNs is still a matter of debate and cannot be a
solid prerequisite to rationally target these lesions with higher
doses of radiation. Therefore, mpMRI should be accompanied by US
fusion-targeted biopsy sampling that will allow the detection and
biological characterization of the IDN.62 Furthermore, the use of
MRI-based radiotherapy planning is still a matter of debate because
of the interobserver variability in GTV contouring and concerns
about geometric distortions from theMRI system and the patient to
be imaged63,64
In our review, we assumed that most investigators aimed at
treating all known visible areas of cancer. We could not obtain in-
formation regarding lesions that could deliberately be excluded
from the boost area and thus could have been underdosed. This
could be the situation in the case where multiple nodules exist in
close contact with organs at risk, and thus, the investigator may
deliberately decide not to boost them to avoid overdosage of
healthy tissue. Indeed, nowadays, it is difﬁcult to ascertainwhich of
the prostate nodules has clinical signiﬁcance and is likely to have an
impact on life expectancy. It is difﬁcult to ascertain if the EBRT dose
delivered to the whole gland is sufﬁcient65e67 to eliminate these
tumors. Thus, this areawill require further clinical studies to be able
to deﬁne the biology of prostate tumors that require dose escalation
treatment and the radiotherapy dose constraints for the OARs that
may limit the delivery of radiation to several dominant nodules.
Clinicians have abandoned the use of posttreatment prostate bi-
opsies, but this may constitute the only method to increase our
knowledge on the biology of the IDN. As clinicians, we should aim
at a better stratiﬁcation of patients far beyond the current use of
clinical prognostic factors. This will allow offering our patients an
individualized cancer treatment with local therapy alone or com-
bination with systemic therapy. To explore this, the Radiation
Therapy Oncology Group has performed immunohistochemical
markers on tissue samples from patients treated in phase III
radiotherapy trials68 (with and without ADT). Immunohistochem-
ical-based assessment of protein cell surface expression for p53,
p16, Cox-2, PKA, Ki-67, MDM2, BCL2, and Bax were analyzed. BothKi-67 and bcl2/bax were independently related to early relapse.
Another approach is to study the somatic tumor genetics on tissue
derived from pretreatment and posttreatment biopsies. The labo-
ratory of Bristow et al has identiﬁed c-MYC, NKX3.1, PTEN, STAR,
and HSD17B2 as adverse prognostic factors after EBRT69e71. Novel
gene signatures reﬂective of the underlying biology of PCa pro-
gression are also being developed in biopsy material and radical
prostatectomy specimens (i.e., Myriad Genetics Prolaris Score,
Genome Health OncotypeDx, Genomic Prostate Score, GenomeDx
Biosciences Decipher, Nuclear Factor kappa B (NF-kB)eactivated
recurrence predictor 2172). Careful monitoring of tumor vasculari-
zation, hypoxia, DNA damagemarkers (i.e., Ku70), the development
of serum biomarkers of CYP17A1, and antigen receptor activity will
be crucial to identify those patients likely to respond to ADT and RT
as well as new combined modality combinations.73
Another important limitation of our series was that it was not
possible to determine the EBRT dose target coverage per lesion. It is
possible in EBRT today to perform heterogeneous planning to
mimic BT dosimetry. In that scenario, tumoricidal “hot spots” are
deliberately located within the tumor while a dose fall-off bath
covers the periphery of the lesion. In that way, the dose to the
periphery of the tumor or the prostate may be compromised to
respect conservative rectal or urethra dose constraints. In-
vestigators have proposed to manipulate urethra doses not to
exceed a maximum of 110% of the prescribed dose although this
raises concerns about reducing cancer control for tumors that are
too close to the urethra74e76. In addition, with the constant physi-
ological movement of the bladder and rectum, the urethra is a
vulnerable organ that may easily get into the high-dose irradiation
area. Therefore, controlling the exact location of the prostate and
the IDN by tracking intraprostatic ﬁducial markers during IGRT
sessions is an obvious method to improve EBRT delivery.
Among all series, there was variability in terms of use of ADT,
which may affect the GTV deﬁnition. For instance, it is uncertain
whether reducing the IDN radiation volume based on neoadjuvant
ADT response may expose the patients to target missing and sub-
sequent risk of recurrence. Our review also highlights the hetero-
geneity in the administration of ADT in most series. Despite the
strong level-1 scientiﬁc evidence supporting the use of ADT to
conventional EBRT in intermediate- and high-risk patients even in
the context of conventional dose escalation up to 78 Gy, only 27.8%
of the patients in our series received ADT. This underutilization of
ADT was recently highlighted by Ong et al77 who prospectively
evaluated 1,806 PCa patients treated in the population-based
Prostate Cancer Outcome Registry Victoria. They reported that
one in ﬁve menwith high-risk PCa and one in twowith unfavorable
intermediate-risk PCa did not receive ADT with RT. It is possible
that in our series, patients have declined standard ADT in the hopes
that experimental higher dose radiation to the prostate could
provide equal disease control with better QoL and especially sexual
QoL compared with the addition of ADT. Based on the current ev-
idence, it is difﬁcult to rule out that dose escalation to the IDN could
provide a beneﬁt on local tumor control in the same magnitude
than the addition of ADT.
Last but not least, our systematic review revealed relatively few
studies with patient-reporting outcomes for assessing toxicity.
Future trials should incorporate global health and prostate-speciﬁc
QoL questionnaires to be able to capture the patient's experience
with these new treatments.
Supplementary Table 3 shows prospective registered clinical
trials that may provide further evidence to implement this tech-
nique in the future11,42,46,78e80.
The most appropriate radiation dose level, dose constraints, the
size of margins, lymph node treatment, and whether neoadjuvant
or adjuvant ADT provides any beneﬁt are variables yet to be
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drawing deﬁnitive conclusions.
5. Conclusion
Keeping in mind the limitations of this systematic review, there
are encouraging results for focal dose escalation to the IDN with
acceptable short- to medium-term side effects and biochemical
disease control rates. However, owing to the heterogeneity of the
studies included, there are many confounding factors limiting the
scope of this review. Considering that the clinical endpoint in the
studies was biochemical recurrence, the use and duration of ADT
administration should be carefully considered before driving
deﬁnitive conclusions. Randomized trials following similar hypo-
fractionated regimens with sufﬁcient follow-up are needed before
this technique can be generally recommended. Therefore, patients
who intend to be treated with a dose escalation to the IDN should
be enrolled in clinical trials.
Conﬂicts of interest
None to be declared.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.prnil.2018.03.005.
References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW,
Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates
for 40 countries in 2012. Eur J Cancer Oxf Engl 1990 2013;49(6):1374e1403.
https://doi.org/10.1016/j.ejca.2012.12.027.
2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A,
Hamavid H, Moradi-Lakeh M, et al. The Global Burden of Cancer 2013. JAMA
Oncol 2015;1(4):505e527. https://doi.org/10.1001/jamaoncol.2015.0735.
3. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome following
active surveillance of men with screen-detected prostate cancer. Results from
the G€oteborg randomised population-based prostate cancer screening trial. Eur
Urol 2013;63(1):101e107. https://doi.org/10.1016/j.eururo.2012.08.066.
4. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in
localized prostate cancer treatment: a meta-analysis of randomized, controlled
trials. Int J Radiat Oncol Biol Phys 2009;74(5):1405e1418. https://doi.org/
10.1016/j.ijrobp.2008.10.091.
5. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static ﬁeld intensity
modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to
seven ﬁeld 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys
1999;44(4):921e929.
6. van Lin ENJT, Fütterer JJ, Heijmink SWTPJ, van der Vight LP, Hoffmann AL, van
Kollenburg P, et al. IMRT boost dose planning on dominant intraprostatic le-
sions: gold marker-based three-dimensional fusion of CT with dynamic
contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys
2006;65(1):291e303. https://doi.org/10.1016/j.ijrobp.2005.12.046.
7. Zaider M, Zelefsky MJ, Lee EK, Zakian KL, Amols HI, Dyke J, et al. Treatment
planning for prostate implants using magnetic-resonance spectroscopy imag-
ing. Int J Radiat Oncol Biol Phys 2000;47(4):1085e1096.
8. Ellis RJ, Zhou H, Kim EY, Fu P, Kaminsky DA, Sodee B, et al. Biochemical disease-
free survival rates following deﬁnitive low-dose-rate prostate brachytherapy
with dose escalation to biologic target volumes identiﬁed with SPECT/CT
capromab pendetide. Brachytherapy 2007;6(1):16e25. https://doi.org/
10.1016/j.brachy.2006.11.002.
9. Pouliot J, Kim Y, Lessard E, Hsu I-C, Vigneron DB, Kurhanewicz J. Inverse
planning for HDR prostate brachytherapy used to boost dominant intra-
prostatic lesions deﬁned by magnetic resonance spectroscopy imaging. Int J
Radiat Oncol Biol Phys 2004;59(4):1196e1207. https://doi.org/10.1016/
j.ijrobp.2004.02.055.
10. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate
cancer radiation dose response: results of the M. D. Anderson phase III ran-
domized trial. Int J Radiat Oncol Biol Phys 2002;53(5):1097e1105.
11. Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen
Suppression Combined with Elective Nodal and Dose Escalated Radiation
Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a
Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-
Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.Int J Radiat Oncol Biol Phys 2017;98(2):275e285. https://doi.org/10.1016/
j.ijrobp.2016.11.026.
12. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al. Randomized trial
comparing iridium implant plus external-beam radiation therapy with
external-beam radiation therapy alone in node-negative locally advanced
cancer of the prostate. J Clin Oncol Off J Am Soc Clin Oncol 2005;23(6):
1192e1199. https://doi.org/10.1200/JCO.2005.06.154.
13. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial
of external beam radiotherapy alone or combined with high-dose-rate
brachytherapy boost for localised prostate cancer. Radiother Oncol J Eur Soc
Ther Radiol Oncol 2012;103(2):217e222. https://doi.org/10.1016/
j.radonc.2012.01.007.
14. Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, et al. ASCENDE-
RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial
Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated
External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J
Radiat Oncol Biol Phys 2017;98(2):286e295. https://doi.org/10.1016/
j.ijrobp.2017.01.008.
15. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach 3rd M, Jung AJ, Carroll PR,
et al. Does local recurrence of prostate cancer after radiation therapy occur at
the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J
Radiat Oncol Biol Phys 2012;82(5):e787e793. https://doi.org/10.1016/
j.ijrobp.2011.11.030.
16. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Analysis
of intraprostatic failures in patients treated with hormonal therapy and
radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol
Biol Phys 2002;53(3):595e599.
17. Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, et al.
Focal therapy for localised unifocal and multifocal prostate cancer: a pro-
spective development study. Lancet Oncol 2012;13(6):622e632. https://
doi.org/10.1016/S1470-2045(12)70121-3.
18. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al.
Clinically signiﬁcant prostate cancer local recurrence after radiation therapy
occurs at the site of primary tumor: magnetic resonance imaging and step-
section pathology evidence. Int J Radiat Oncol Biol Phys 2007;69(1):62e69.
https://doi.org/10.1016/j.ijrobp.2007.03.065.
19. Huang CC, Deng F-M, Kong MX, Ren Q, Melamed J, Zhou M. Re-evaluating the
concept of “dominant/index tumor nodule” in multifocal prostate cancer.
Virchows Arch Int J Pathol 2014;464(5):589e594. https://doi.org/10.1007/
s00428-014-1557-y.
20. Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, et al. Ad-
vances in magnetic resonance imaging: how they are changing the manage-
ment of prostate cancer. Eur Urol 2011;59(6):962e977. https://doi.org/
10.1016/j.eururo.2011.02.034.
21. Chang JH, Joon DL, Lee ST, Gong SJ, Scott AM, Davis ID, et al. Histopathological
correlation of (11)C-choline PET scans for target volume deﬁnition in radical
prostate radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 2011;99(2):
187e192. https://doi.org/10.1016/j.radonc.2011.03.012.
22. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in
prostate cancer management. Nat Rev Urol 2016;13(4):226e235. https://
doi.org/10.1038/nrurol.2016.26.
23. Simmons LAM, Autier P, Zat’ura F, Braeckman J, Peltier A, Romic I, et al.
Detection, localisation and characterisation of prostate cancer by prostate
HistoScanning(TM). BJU Int 2012;110(1):28e35. https://doi.org/10.1111/j.1464-
410X.2011.10734.x.
24. Zhu Y, Chen Y, Qi T, Jiang J, Qi J, Yu Y, et al. Prostate cancer detection with real-
time elastography using a bi-plane transducer: comparison with step section
radical prostatectomy pathology. World J Urol 2014;32(2):329e333. https://
doi.org/10.1007/s00345-012-0922-1.
25. Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, et al. Improved
clinical outcomes with high-dose image guided radiotherapy compared
with non-IGRT for the treatment of clinically localized prostate cancer. Int J
Radiat Oncol Biol Phys 2012;84(1):125e129. https://doi.org/10.1016/
j.ijrobp.2011.11.047.
26. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of
the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys
2008;72(1):236e246. https://doi.org/10.1016/j.ijrobp.2008.04.051.
27. Klayton T, Price R, Buyyounouski MK, Sobczak M, Greenberg R, Li J, et al.
Prostate bed motion during intensity-modulated radiotherapy treatment. Int J
Radiat Oncol Biol Phys 2012;84(1):130e136. https://doi.org/10.1016/
j.ijrobp.2011.11.041.
28. Zelefsky MJ, Cohen G, Zakian KL, Dyke J, Koutcher JA, Hricak H, et al. Intra-
operative conformal optimization for transperineal prostate implantation us-
ing magnetic resonance spectroscopic imaging. Cancer J Sudbury Mass
2000;6(4):249e255.
29. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, et al.
Magnetic resonance spectroscopic imaging-guided brachytherapy for localized
prostate cancer. Int J Radiat Oncol Biol Phys 2002;52(2):429e438.
30. De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, et al.
The magnetic resonance detected intraprostatic lesion in prostate cancer:
planning and delivery of intensity-modulated radiotherapy. Radiother Oncol J
Eur Soc Ther Radiol Oncol 2005;75(3):325e333. https://doi.org/10.1016/
j.radonc.2005.04.014.
31. Singh AK, Guion P, Sears-Crouse N, Ullman K, Smith S, Albert PS, et al. Simul-
taneous integrated boost of biopsy proven, MRI deﬁned dominant intra-
Prostate International 6 (2018) 75e8786prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study.
Radiat Oncol Lond Engl 2007;2:36. https://doi.org/10.1186/1748-717X-2-36.
32. Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, et al.
Intensity-modulated radiotherapy as primary therapy for prostate cancer:
report on acute toxicity after dose escalation with simultaneous integrated
boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008;72(3):799e807.
https://doi.org/10.1016/j.ijrobp.2008.01.040.
33. Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, et al.
Hypofractionated boost with high-dose-rate brachytherapy and open magnetic
resonance imaging-guided implants for locally aggressive prostate cancer: a
sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys 2009;75(3):
656e663. https://doi.org/10.1016/j.ijrobp.2008.11.023.
34. Miralbell R, Molla M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, et al. Hypo-
fractionated boost to the dominant tumor region with intensity modulated
stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot
study. Int J Radiat Oncol Biol Phys 2010;78(1):50e57. https://doi.org/10.1016/
j.ijrobp.2009.07.1689.
35. Schick U, Popowski Y, Nouet P, Bieri S, Rouzaud M, Khan H, et al. High-dose-
rate brachytherapy boost to the dominant intra-prostatic tumor region: hemi-
irradiation of prostate cancer. Prostate 2011;71(12):1309e1316. https://
doi.org/10.1002/pros.21347.
36. Ellis RJ, Zhou H, Kaminsky DA, Fu P, Kim EY, Sodee DB, et al. Rectal morbidity
after permanent prostate brachytherapy with dose escalation to biologic target
volumes identiﬁed by SPECT/CT fusion. Brachytherapy 2007;6(2):149e156.
https://doi.org/10.1016/j.brachy.2007.01.006.
37. Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen WD, Brelin A, et al. Ten-year out-
comes: the clinical utility of single photon emission computed tomography/
computed tomography capromab pendetide (Prostascint) in a cohort diag-
nosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;81(1):
29e34. https://doi.org/10.1016/j.ijrobp.2010.05.053.
38. Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, et al. Image-
guided radiotherapy for prostate cancer: a prospective trial of concomitant
boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J
Radiat Oncol Biol Phys 2011;81(4):e423e429. https://doi.org/10.1016/
j.ijrobp.2011.01.048.
39. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-esca-
lation using intensity-modulated radiotherapy for prostate cancer - evaluation
of quality of life with and without (18)F-choline PET-CT detected simultaneous
integrated boost. Radiat Oncol Lond Engl 2012;7:14. https://doi.org/10.1186/
1748-717X-7-14.
40. Ippolito E, Mantini G, Morganti AG, Mazzeo E, Padula GD, Digesù C, et al. In-
tensity-modulated radiotherapy with simultaneous integrated boost to domi-
nant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol
2012;35(2):158e162. https://doi.org/10.1097/COC.0b013e318209cd8f.
41. Myers MA, Hagan MP, Todor D, Gilbert L, Mukhopadhyay N, Randolf J, et al.
Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypo-
fractionated intensity-modulated radiation therapy for localized adenocarci-
noma of the prostate. Brachytherapy 2012;11(4):292e298. https://doi.org/
10.1016/j.brachy.2011.07.006.
42. Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I-K,
Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible
tumor as monotherapy for low- and intermediate-risk prostate cancer: early
results. Radiat Oncol Lond Engl 2013;8:84. https://doi.org/10.1186/1748-717X-
8-84.
43. Schild MH, Schild SE, Wong WW, Vora SA, Silva AC, Silva AM, et al. Early
Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorpo-
rating a Simultaneous Intra-Prostatic MRI Directed Boost. OMICS J Radiol
2014;3(4). https://doi.org/10.4172/2167-7964.1000170.
44. Gomez-Iturriaga A, Casquero F, Urresola A, Ezquerro A, Lopez JI, Espinosa JM,
et al. Dose escalation to dominant intraprostatic lesions with MRI-transrectal
ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II
trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 2016;119(1):91e96. https://
doi.org/10.1016/j.radonc.2016.02.004.
45. King MT, Nasser NJ, Mathur N, Cohen GN, Kollmeier MA, Yuen J, et al. Long-
term outcome of magnetic resonance spectroscopic image-directed dose
escalation for prostate brachytherapy. Brachytherapy 2016;15(3):266e273.
https://doi.org/10.1016/j.brachy.2016.02.003.
46. Sundahl N, De Meerleer G, Villeirs G, Ost P, De Neve W, Lumen N, et al.
Combining high dose external beam radiotherapy with a simultaneous inte-
grated boost to the dominant intraprostatic lesion: Analysis of genito-urinary
and rectal toxicity. Radiother Oncol J Eur Soc Ther Radiol Oncol 2016;119(3):
398e404. https://doi.org/10.1016/j.radonc.2016.04.031.
47. Kotecha R, Djemil T, Tendulkar RD, Reddy CA, Thousand RA, Vassil A, et al.
Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Inter-
mediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient
Outcomes. Int J Radiat Oncol Biol Phys 2016;95(3):960e964. https://doi.org/
10.1016/j.ijrobp.2016.02.009.
48. Uzan J, Nahum AE, Syndikus I. Prostate Dose-painting Radiotherapy and
Radiobiological Guided Optimisation Enhances the Therapeutic Ratio. Clin
Oncol R Coll Radiol G B 2016;28(3):165e170. https://doi.org/10.1016/
j.clon.2015.09.006.
49. Garibaldi E, Delmastro E, Gabriele D, Bresciani S, Russo F, Di Dia A, et al. Clinical
and technical feasibility of ultra-boost irradiation in Dominant Intraprostatic
Lesion by Tomotherapy: preliminary experience and revision of literature.
Panminerva Med 2016;58(1):16e22.50. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate
carcinoma. Int J Radiat Oncol Biol Phys 1999;43(5):1095e1101.
51. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols
should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56(4):
1093e1104.
52. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, et al. Dose-escalation
using intensity-modulated radiotherapy for prostate cancereevaluation of the
dose distribution with and without 18F-choline PET-CT detected simultaneous
integrated boost. Radiother Oncol J Eur Soc Ther Radiol Oncol 2009;93(2):
213e219. https://doi.org/10.1016/j.radonc.2009.07.014.
53. Hannan R, Tumati V, Xie X-J, Cho LC, Kavanagh BD, Brindle J, et al. Stereotactic
body radiation therapy for low and intermediate risk prostate cancer-Results
from a multi-institutional clinical trial. Eur J Cancer Oxf Engl 1990 2016;59:
142e151. https://doi.org/10.1016/j.ejca.2016.02.014.
54. Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel
Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosi-
metric and Clinical Effects of Perirectal Spacer Application in Men Undergoing
Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat
Oncol Biol Phys 2015;92(5):971e977. https://doi.org/10.1016/
j.ijrobp.2015.04.030.
55. Ma JL, Hennessey DB, Newell BP, Bolton DM, Lawrentschuk N. Radiotherapy-
related complications presenting to a urology department - a more common
problem than previously thought? BJU Int January 2018. https://doi.org/
10.1111/bju.14145.
56. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic
body radiotherapy for localized prostate cancer: pooled analysis from a multi-
institutional consortium of prospective phase II trials. Radiother Oncol J Eur Soc
Ther Radiol Oncol 2013;109(2):217e221. https://doi.org/10.1016/
j.radonc.2013.08.030.
57. Bott SRJ, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M.
The index lesion and focal therapy: an analysis of the pathological character-
istics of prostate cancer. BJU Int 2010;106(11):1607e1611. https://doi.org/
10.1111/j.1464-410X.2010.09436.x.
58. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med
2009;361(17):1704e1706. https://doi.org/10.1056/NEJMcibr0905562.
59. Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR. Transrectal ul-
trasonography-guided biopsy does not reliably identify dominant cancer
location in men with low-risk prostate cancer. BJU Int 2012;110(1):50e55.
https://doi.org/10.1111/j.1464-410X.2011.10704.x.
60. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, et al. Dynamic
contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic
prostate cancer: correlation with radical prostatectomy specimens. Urology
2009;74(5):1094e1099. https://doi.org/10.1016/j.urology.2009.04.102.
61. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast
enhanced, pelvic phased array magnetic resonance imaging of localized pros-
tate cancer for predicting tumor volume: correlation with radical prostatec-
tomy ﬁndings. J Urol 2006;176(6 Pt 1):2432e2437. https://doi.org/10.1016/
j.juro.2006.08.007.
62. Gomez-Iturriaga A, Casquero F, Lopez JI, Urresola A, Ezquerro A, Buscher D,
et al. Transperineal biopsies of MRI-detected aggressive index lesions in low-
and intermediate-risk prostate cancer patients: Implications for treatment
decision. Brachytherapy 2017;16(1):201e206. https://doi.org/10.1016/
j.brachy.2016.11.004.
63. Adjeiwaah M, Bylund M, Lundman JA, Karlsson CT, Jonsson JH, Nyholm T.
Quantifying the Effect of 3T Magnetic Resonance Imaging Residual System
Distortions and Patient-Induced Susceptibility Distortions on Radiation Ther-
apy Treatment Planning for Prostate Cancer. Int J Radiat Oncol Biol Phys
October 2017. https://doi.org/10.1016/j.ijrobp.2017.10.021.
64. Rischke HC, Nestle U, Fechter T, Doll C, Volegova-Neher N, Henne K, et al. 3
Tesla multiparametric MRI for GTV-deﬁnition of Dominant Intraprostatic Le-
sions in patients with Prostate Cancerean interobserver variability study.
Radiat Oncol Lond Engl 2013;8:183. https://doi.org/10.1186/1748-717X-8-183.
65. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number
analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat
Med 2009;15(5):559e565. https://doi.org/10.1038/nm.1944.
66. Van der Kwast TH. The trade-off between sensitivity and speciﬁcity of clinical
protocols for identiﬁcation of insigniﬁcant prostate cancer. Eur Urol
2012;62(3):469e471. https://doi.org/10.1016/j.eururo.2012.04.017.
67. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The
mutational landscape of lethal castration-resistant prostate cancer. Nature
2012;487(7406):239e243. https://doi.org/10.1038/nature11125.
68. Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, et al.
Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With
Radiotherapy for Prostate Cancer. J Natl Cancer Inst 2017;109(2):1e8. https://
doi.org/10.1093/jnci/djw232.
69. Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, et al. Copy
number alterations of c-MYC and PTEN are prognostic factors for relapse after
prostate cancer radiotherapy. Cancer 2012;118(16):4053e4062. https://
doi.org/10.1002/cncr.26729.
70. Locke JA, Zafarana G, Malloff CA, LamWL, Sykes J, Pintilie M, et al. Allelic loss of
the loci containing the androgen synthesis gene, StAR, is prognostic for relapse
in intermediate-risk prostate cancer. Prostate 2012;72(12):1295e1305.
https://doi.org/10.1002/pros.22478.
71. Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, et al. NKX3.1
haploinsufﬁciency is prognostic for prostate cancer relapse following surgery
T. Feutren and F.G. Herrera / Prostate irradiation with focal IDN boost: systematic review 87or image-guided radiotherapy. Clin Cancer Res Off J Am Assoc Cancer Res.
2012;18(1):308e316. https://doi.org/10.1158/1078-0432.CCR-11-2147.
72. Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG. Mechanistic Insights into
Molecular Targeting and Combined Modality Therapy for Aggressive, Localized
Prostate Cancer. Front Oncol 2016;6:24. https://doi.org/10.3389/
fonc.2016.00024.
73. McGrath S, Christidis D, Perera M, Hong SK, Manning T, Vela I, et al. Prostate
cancer biomarkers: Are we hitting the mark? Prostate Int 2016;4(4):130e135.
https://doi.org/10.1016/j.prnil.2016.07.002.
74. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body
radiation therapy (SBRT) for clinically localized prostate cancer: the George-
town University experience. Radiat Oncol Lond Engl 2013;8:58. https://doi.org/
10.1186/1748-717X-8-58.
75. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for
localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy
and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008;70(5):
1588e1597. https://doi.org/10.1016/j.ijrobp.2007.11.067.
76. Vainshtein J, Abu-Isa E, Olson KB, Ray ME, Sandler HM, Normolle D, et al.
Randomized phase II trial of urethral sparing intensity modulated radia-
tion therapy in low-risk prostate cancer: implications for focal therapy.Radiat Oncol Lond Engl 2012;7:82. https://doi.org/10.1186/1748-717X-7-
82.
77. Ong WL, Foroudi F, Evans S, Millar J. Large institutional variations in use of
androgen deprivation therapy with deﬁnitive radiotherapy in a population-
based cohort of men with intermediate- and high-risk prostate cancer. BJU Int
2017;120(Suppl 3):35e42. https://doi.org/10.1111/bju.13969.
78. Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al.
Preliminary toxicity analysis of 3-dimensional conformal radiation therapy
versus intensity modulated radiation therapy on the high-dose arm of the
Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat
Oncol Biol Phys 2013;87(5):932e938. https://doi.org/10.1016/
j.ijrobp.2013.07.041.
79. Zietman AL, DeSilvio ML, Slater JD, Rossi Jr CJ, Miller DW, Adams JA, et al.
Comparison of conventional-dose vs high-dose conformal radiation therapy in
clinically localized adenocarcinoma of the prostate: a randomized controlled
trial. J Am Med Assoc 2005;294(10):1233e1239. https://doi.org/10.1001/
jama.294.10.1233.
80. Katz AJ, Kang J. Quality of Life and Toxicity after SBRT for Organ-Conﬁned
Prostate Cancer, a 7-Year Study. Front Oncol 2014;4:301. https://doi.org/
10.3389/fonc.2014.00301.
